Unknown

Dataset Information

0

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis.


ABSTRACT: Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with myelofibrosis. Patients and Methods Patients (N = 432) with high risk or intermediate-2 risk or symptomatic intermediate-1 risk myelofibrosis were randomly assigned to receive 24 weeks of treatment with momelotinib 200 mg once daily or ruxolitinib 20 mg twice a day (or per label), after which all patients could receive open-label momelotinib. The primary end point was a ? 35% reduction in spleen volume at 24 weeks of therapy. Secondary end points were rates of symptom response and effects on RBC transfusion requirements. Results A ? 35% reduction in spleen volume at week 24 was achieved by a similar proportion of patients in both treatment arms: 26.5% of the momelotinib group and 29% of the ruxolitinib group (noninferior; P = .011). A ? 50% reduction in the total symptom score was observed in 28.4% and 42.2% of patients who received momelotinib and ruxolitinib, respectively, indicating that noninferiority was not met ( P = .98). Transfusion rate, transfusion independence, and transfusion dependence were improved with momelotinib (all with nominal P ? .019). The most common grade ? 3 hematologic abnormalities in either group were thrombocytopenia and anemia. Grade ? 3 infections occurred in 7% of patients who received momelotinib and 3% of patients who received ruxolitinib. Treatment-emergent peripheral neuropathy occurred in 10% of patients who received momelotinib (all grade ? 2) and 5% of patients who received ruxolitinib (all grade ? 3). Conclusion In JAKi-naïve patients with myelofibrosis, 24 weeks of momelotinib treatment was noninferior to ruxolitinib for spleen response but not for symptom response. Momelotinib treatment was associated with a reduced transfusion requirement.

SUBMITTER: Mesa RA 

PROVIDER: S-EPMC6553796 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

Mesa Ruben A RA   Kiladjian Jean-Jacques JJ   Catalano John V JV   Devos Timothy T   Egyed Miklos M   Hellmann Andrzei A   McLornan Donal D   Shimoda Kazuya K   Winton Elliott F EF   Deng Wei W   Dubowy Ronald L RL   Maltzman Julia D JD   Cervantes Francisco F   Gotlib Jason J  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20170920 34


Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with myelofibrosis. Patients and Methods Patients (N = 432) with high risk or intermediate-2 risk or symptomatic intermediate-1 risk myelofibrosis were randomly assigned to receive 24 weeks of treatment with momelotinib 200 mg once daily or ruxolitinib 20 mg twice a day (or per label), after which all patients could receive o  ...[more]

Similar Datasets

| S-EPMC5025038 | biostudies-other
| S-EPMC10225216 | biostudies-literature
| S-EPMC3627327 | biostudies-literature
| S-EPMC10875410 | biostudies-literature
| S-EPMC10852065 | biostudies-literature
| S-EPMC10092883 | biostudies-literature
| S-EPMC7282206 | biostudies-literature
| S-EPMC8207822 | biostudies-literature
| S-EPMC8358255 | biostudies-literature
2022-03-05 | GSE197811 | GEO